QIAGEN OmicSoft and Biomedical Knowledge Base
Using OmicSoft OncoLand to integrate public expression and somatic mutation data for biomarker discovery
356 views
QIAGEN OmicSoft Lands are high-quality curated repositories of genomics and proteomics data sourced from public, published studies (GEO, EBI, SRA) and consortia (TCGA, CPTAC, GTEx, and more). Because of our expert curation and stringent quality checks, OmicSoft users can deeply investigate across diverse oncology and normal tissue/cell datasets to discover and validate candidate drug targets and biomarkers.
In this training, attendees will use OmicSoft Studio, our graphical user interface, to access public data from The Cancer Genome Atlas (TCGA). Using this data, you will learn how to:
• View gene expression and somatic mutation frequency across different tumor types and conditions
• Identify genes whose expression correlates or anti-correlates with mutation of your target
• Prioritize your candidate biomarkers using expression data across comparisons (tumor vs. normal, MUT vs. WT, etc.)
• Establish survival consequences from changes in your candidate biomarker’s expression or mutation status
Related videos
QIAGEN OmicSoft and Biomedical Knowledge Base
Knowledge graphs and more: Analytics-driven drug discovery using advanced biomedical...
High-quality biomedical relationships knowledge is the cornerstone of modern...
QIAGEN IPA
Discovery from public oncological data using QIAGEN Omicsoft OncoLand and QIAGEN Ingenuity...
In this 90-minute training, we will discuss how to discover and validate...
QIAGEN OmicSoft and Biomedical Knowledge Base
Supercharge your AI in drug discovery with high-quality biomedical data
If you’re working in pharma or biotech, you likely rely on artificial...